- Using Ascletis' proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback